German committee finalizes assessments for Zelboraf, Caprelsa

Germany's Federal Joint Committee (G-BA) issued final benefit assessments for cancer drugs Zelboraf vemurafenib and Caprelsa vandetanib that are in line with preliminary assessments from the Institute for Quality and Efficiency in Health Care (IQWiG). G-BA said Zelboraf from Roche (SIX:ROG; OTCQX:RHHBY) provides "significant" additional benefit over dacarbazine for patients with unresectable or metastatic melanoma who are BRAF V600-mutation positive. Roche will now negotiate a price for Zelboraf with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband). ...